Mark Stolper

This profile gathers the share dealings of Mark Stolper across 3 companies, led by RadNet, Inc., Surgalign Holdings, Inc. and Starling Oncology, Inc. Between 4 January 2016 and 27 July 2026, the trades on record add up to 15 filings.

Every open-market trade on record is a sale: 2 sales worth €3.6M. Outside the open market, there are 9 share grants and 1 option exercise.

Most recently, on 29 July 2026, the filings show a share grant in Starling Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.